CTNNB1 and hepatocellular carcinoma: Considering the limitation of the ICI score that can only be obtained by transcriptome analysis of surgical specimens, we analyzed the somatic mutation genes in the high and low score groups to screen potential biomarkers for HCC immunotherapy and found that the ICI score was significantly increased in patients with CTNNB1 mutation.